floxuridine has been researched along with Cachexia in 8 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cancer cachexia is a common paraneoplastic syndrome in patients with advanced malignancies." | 5.30 | [Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model]. ( Arime, I; Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y, 1999) |
| "The figures in patients with breast cancer were: 1,761 days (58." | 3.78 | [Survival and changes of clinical laboratory data in phase II study with 5'-DFUR]. ( Taguchi, T, 1996) |
| " The degree of synergism between docetaxel and two oral fluoropyrimidines, tegafur and 5'-deoxy-5-fluorouridine (5'-dFUrd), was investigated in the KPL-4 human breast cancer xenograft model." | 3.71 | Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts. ( Kunisue, H; Kurebayashi, J; Kurosumi, M; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, S, 2001) |
| "Cancer cachexia is a common paraneoplastic syndrome in patients with advanced malignancies." | 1.30 | [Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model]. ( Arime, I; Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto-Ouchi, K | 1 |
| Tamura, S | 1 |
| Mori, K | 1 |
| Ishikawa, T | 2 |
| Eda, H | 3 |
| Tanaka, Y | 4 |
| Ninomiya, Y | 1 |
| Ishitsuka, H | 4 |
| Taguchi, T | 1 |
| Okamura, A | 1 |
| Ohmura, Y | 1 |
| Islam, MM | 1 |
| Tagawa, M | 1 |
| Horitsu, K | 1 |
| Moriyama, Y | 1 |
| Fujimura, S | 1 |
| Yamamoto, S | 2 |
| Kurebayashi, J | 2 |
| Kunisue, H | 2 |
| Udagawa, K | 1 |
| Yamamoto, Y | 1 |
| Arime, I | 1 |
| Tanaka, K | 2 |
| Shimozuma, K | 1 |
| Sonoo, H | 2 |
| Hussey, HJ | 1 |
| Todorov, PT | 1 |
| Field, WN | 1 |
| Inagaki, N | 1 |
| Tisdale, MJ | 1 |
| Kurosumi, M | 1 |
| Otsuki, T | 1 |
| Fujimoto, K | 1 |
| Tanaka, T | 1 |
1 review available for floxuridine and Cachexia
| Article | Year |
|---|---|
[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Cachexia; | 1996 |
1 trial available for floxuridine and Cachexia
| Article | Year |
|---|---|
[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Cachexia; | 1996 |
7 other studies available for floxuridine and Cachexia
| Article | Year |
|---|---|
[Antitumor activity of various cytostatics in mice bearing murine advanced tumors].
Topics: Animals; Antineoplastic Agents; Cachexia; Cyclophosphamide; Drug Screening Assays, Antitumor; Floxur | 1993 |
Increased hepatic nicotinamide N-methyltransferase activity as a marker of cancer cachexia in mice bearing colon 26 adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cachexia; Colonic Neoplasms; Floxuridine; Liver; Methyltransferases; Mice; | 1998 |
[Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cachexia; Cell Division; Female; Floxuridine; Huma | 1999 |
Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Appetite Stimulants; Blood Proteins; Body | 2000 |
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cachexia; Docetaxel; Drug Interactions; | 2001 |
Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma.
Topics: Acute-Phase Proteins; Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cachexia; C | 1990 |
5'-Deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cachexia; Cell Division; Colonic Neoplasms; Drug Res | 1991 |